What is it about?
Urological cancers, especially of the bladder and prostate, are still a mess to treat. Relapse is common. Side effects pile up. And for all the talk of precision medicine, many therapies still hit healthy tissue almost as hard as tumors. Phytochemicals often get pitched as a cleaner alternative. In lab studies, they stop cancer cells from dividing, push them toward self-destruction, and slow invasion.
Featured Image
Photo by julien Tromeur on Unsplash
Why is it important?
On paper, it sounds great. In practice, not so much. These compounds dissolve poorly, vanish quickly from circulation, and rarely reach tumors in meaningful amounts. Nanotechnology is now being sold as the fix.
Perspectives
The idea is simple enough: wrap phytochemicals in nanoscale carriers, guide them to tumors, and control when the drug is released. This chapter takes a hard look at how that promise is playing out, covering lipid, polymeric, inorganic, and hybrid nanocarriers. It also tracks claims around better imaging, immune effects, gene delivery, and light-based therapies. Bibliometric data adds context, showing who is publishing, partnering, and setting the agenda. The takeaway is cautious optimism, not hype.
Dr Bikram Jit Singh
MMDU Mullana
Read the Original
This page is a summary of: Nanotechnology-Mediated Targeted Delivery of Phytochemicals in Urological Cancers, January 2026, Springer Science + Business Media,
DOI: 10.1007/978-981-92-1158-6_8.
You can read the full text:
Contributors
The following have contributed to this page
